With more than three weeks left in the first quarter, the value of med-tech IPOs for 2025 already exceeds the funds raised ...

A slow-down in EU medical device audits due to the long-delayed transition to the EU Medical Device Regulation is leading to ...

Lysine demethylase 6A (KDM6A) is a demethylase that plays a key role at regulating developmental gene expression signatures ...

Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with a high mortality rate and characterized by ...

A new multi-omics approach to unpicking how noncoding gene variants influence the development of common chronic diseases has ...

Boehringer Ingelheim GmbH terminated its second metabolic dysfunction-associated steatohepatitis (MASH) alliance on March 6, ending an $870 million license agreement inked with Yuhan Corp. for dual ...

Researchers from Revolo Biotherapeutics Ltd. recently presented preclinical data for IRL-201104, a clinical-stage ...

Fragile X syndrome (FXS) is the most common inherited form of intellectual disability and a leading monogenic cause of autism, yet effective treatments remain elusive. Previous work showed that ...

Histone deacetylase 3 (HDAC3) is involved in transcriptional regulation, phosphorylation and the inhibition of tumor suppressor genes. Its upregulation in several types of tumors, such as colorectal, ...

Biopharma companies raised $2.98 billion through 59 transactions in February 2025, down from $5.91 billion across 93 deals in January. The year is off to a slower start compared to 2023, with the ...

Researchers from General Hospital of Tianjin Medical University presented data from a study that aimed to explore the role of NIMA-related kinase 2 (NEK2) in regulating B-cell immunity in autoimmune ...

There have been plenty of multi-billion-dollar mega mergers in the past few years but most have fallen short of their goals. In the latest edition of the BioWorld Insider podcast, Karen Carey, ...